In connection with the Underwritten Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 703,703 ordinary shares at a price of $20.25 per share.

Oculis intends to use the net proceeds from the financing to advance and accelerate the development of its novel neuroprotective clinical candidate, Privosegtor in acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), as well as for working capital and general corporate purposes.

The financing consists of an underwritten offering (the “Underwritten Offering”) of 4,691,358 ordinary shares and a registered direct offering to an investor of 740,740 ordinary shares (the “Direct Offering” and, together with the Underwritten Offering, the “Offerings”). The Offerings are expected to close on or about November 3, 2025, subject to satisfaction of customary closing conditions. Of the shares being offered, including shares underlying the underwriters’ option, 2,635,801 are new shares that will be issued out of the Company’s existing capital band ( Kapitalband) before closing and 3,500,000 are shares previously held in treasury by the Company. The issuance of the new shares will bring the total number of registered shares authorized by the Company as per its Articles of Association up to 57,169,475.

J.P. Morgan, Leerink Partners and Pareto Securities are acting as joint bookrunning managers for the Underwritten Offering. Van Lanschot Kempen is acting as manager for the Underwritten Offering. Arctica Finance is acting as financial advisor for the Underwritten Offering.